Notes
total Psoriasis Area and Severity Index (PASI) score ≥10 and Dermatology Life Quality Index (DLQI) score >10
Reference
National Institute for Health and Care Excellence. Final appraisal determination Ixekizumab for treating moderate to severe plaque psoriasis Internet Document : Mar 2017. Available from: URL: https://www.nice.org.uk/guidance/GID-TA10063/documents/final-appraisal-determination-document
Rights and permissions
About this article
Cite this article
NICE recommends ixekizumab for severe plaque psoriasis. PharmacoEcon Outcomes News 774, 37 (2017). https://doi.org/10.1007/s40274-017-3861-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3861-7